Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Pediatric-Based Versus Adult Treatment Protocols in Young Adults (18-40 years) with Standard Risk Acute Lymphoblastic Leukemia: The BC Cancer Agency Experience

David Simon Kliman, MBBS, Michael J Barnett, BMBS, FRCPC, FRCP, FRCPath, Raewyn Broady, MBChB, FRACP, Donna L. Forrest, MD FRCPC, Alina S. Gerrie, MD MPH, FRCPC, Donna E. Hogge, MD PhD FRCPC, Stephen H. Nantel, MD FRCPC, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Thomas J. Nevill, MD FRCPC, Maryse M Power, MB, MRCPI, FRCPath, Kevin Song, MD FRCPC, Heather J. Sutherland, MD PhD FRCPC, Cynthia L. Toze, MD MHSc, FRCPC, Yasser Abou Mourad, MD FRCPC

Blood (2015) 126 (23): 3770.

https://doi.org/10.1182/blood.V126.23.3770.3770

Published: 2015

Journal Articles

Prognostic Factors and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Vs. Non-Transplant Chronic Lymphocytic Leukemia (CLL) Patients: A Comparative Analysis with the Leukemia/BMT Program of British Columbia (BC) and the BC Provincial CLL Database

Sebastian J. Swic, Alexander G. T. MacPhail, Chinmay B. Dalal, MD, Steven J.T. Huang, BMLSc, Alina S. Gerrie, MD FRCPC, Thomas J. Nevill, MD, Heather J. Sutherland, MD PhD FRCPC, Raewyn Broady, MBChB, Stephen H. Nantel, MD FRCPC, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Kevin Song, MD, Yasser R Abou Mourad, MD FRCPC, Donna E. Hogge, MD PhD FRCPC, Maryse M. Power, MD MRCPI, FRCPath, Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Donna L. Forrest, MD, Sean S Young, PhD DABMG, FACMG, FCCMG, Tanya L. Gillan, PhD FCCMG, Cynthia L. Toze, MD FRCPC

Blood (2014) 124 (21): 2549.

https://doi.org/10.1182/blood.V124.21.2549.2549

Published: 2014

Journal Articles

Improved Survival In Adults With Mixed-Phenotype Acute Leukemia Following Stem Cell Transplantation (SCT): A Single Centre Experience

Mallikarjun Kalashetty, MBBS, MD, DM, Bakul I. Dalal, MD, FRCPC, Kristine J Roland, MD, FRCPC, Yasser Abou Mourad, MD, Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Raewyn Broady, MBChB, Donna L. Forrest, MD, Donna E. Hogge, MD, PhD, FRCPC, Alina S. Gerrie, MD, Stephen H. Nantel, MD, FRCPC, Maryse Power, MD, Kevin W. Song, MD, FRCPC, Heather J. Sutherland, MD, PhD, FRCPC, Cynthia L. Toze, MD, MHSc, FRCPC, Thomas J. Nevill, MD, FRCPC, John D. Shepherd, MD, Sujaatha Narayanan, MBBS, MRCP, FRCPath

Blood (2013) 122 (21): 5540.

https://doi.org/10.1182/blood.V122.21.5540.5540

Published: 2013

Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 2682.

https://doi.org/10.1182/blood.V122.21.2682.2682

Published: 2013

Journal Articles

Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia

Blood (2013) 122 (21): 1788.

https://doi.org/10.1182/blood.V122.21.1788.1788

Published: 2013

Journal Articles

Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy

Mark D. Minden, MD, PhD, FRCPC, Donna E. Hogge, MD, PhD, FRCPC, Scott Weir, PharmD, PhD, Jim Kasper, MS, Lavonne Patton, PhD, Yulia Jitkova, PhD, Marcela Gronda, MSc, Rose Hurren, BSc, Lian Rajewski, Kevin Schorno, MBA, Hong Chang, Joseph M. Brandwein, MD, Vikas Gupta, MD, FRCP, FRCPath, Andre C. Schuh, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Karen W.L. Yee, MD, FRCP, Greg Reed, Aaron D Schimmer, MD, PhD

Blood (2012) 120 (21): 1372.

https://doi.org/10.1182/blood.V120.21.1372.1372

Published: 2012

Journal Articles

Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort

Chinmay B. Dalal, MD, Chandrakala Shanmukhaiah, MD, Thomas J. Nevill, MD, FRCPC, Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Stephen H. Nantel, MD, FRCPC, Donna E. Hogge, MD, PhD, FRCPC, Donna L. Forrest, MD, FRCPC, Heather J. Sutherland, MD, PhD, FRCPC, Kevin W. Song, MD, FRCPC, Raewyn Broady, MBChB, FRACP, Maryse M. Power, MD, MRCPI, FRCPath, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Yasser R Abou Mourad, MD, FRCPC, John D. Shepherd, MD, FRCPC, Sean S Young, PhD, DABMG, FACMG, FCCMG, Tanya L. Gillan, PhD, FCCMG, Cynthia L. Toze, MD, MHSc, FRCPC

Blood (2012) 120 (21): 4132.

https://doi.org/10.1182/blood.V120.21.4132.4132

Published: 2012

Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD

Blood (2012) 120 (21): 3625.

https://doi.org/10.1182/blood.V120.21.3625.3625

Published: 2012

Journal Articles

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

Jeffrey E Lancet, MD, Jorge E Cortes, MD, Tibor Kovacsovics, MD, Donna E. Hogge, MD, PhD, FRCPC, Jonathan E. Kolitz, MD, Martin S Tallman, MD, Antje Hoering, PhD, Michael T. Chiarella, Arthur C. Louie, MD, Eric Feldman, MD

Blood (2012) 120 (21): 3626.

https://doi.org/10.1182/blood.V120.21.3626.3626

Published: 2012

Journal Articles

Allogeneic Stem Cell Transplant in First Complete Remission Overcomes the Poor Prognosis Associated with the FLT-3 Internal Tandem Duplication in Acute Myeloid Leukemia.

Maryse M. Power, MRCPI, MRCPath, Giovanna Di Sauro, Angela Brooks-Wilson, Thomas J. Nevill, MD, FRCPC, Julye C. Lavoie, MD, Clayton A. Smith, MD, John D. Shepherd, MD, FRCPC, Cindy L. Toze, MD, FRCPC, MHSc, Heather J. Sutherland, MD, FRCPC, PhD, Michael J. Barnett, MB, FRCPath, Yasser A. Abou Mourad, MD, Kevin W. Song, MD, FRCPC, Donna M. Forrest, MD, FRCPC, Steven H. Nantel, MD, FRCPC, Stanley C. Wong, Anna A. Krasnova, Ryan Brinkman, PhD, Donna E. Hogge, MD, PhD, FRCPC

Blood (2007) 110 (11): 3491.

https://doi.org/10.1182/blood.V110.11.3491.3491

Published: 2007

NARROW

Pediatric-Based Versus Adult Treatment Protocols in Young Adults (18-40 years) with Standard Risk Acute Lymphoblastic Leukemia: The BC Cancer Agency Experience

Prognostic Factors and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Vs. Non-Transplant Chronic Lymphocytic Leukemia (CLL) Patients: A Comparative Analysis with the Leukemia/BMT Program of British Columbia (BC) and the BC Provincial CLL Database

Improved Survival In Adults With Mixed-Phenotype Acute Leukemia Following Stem Cell Transplantation (SCT): A Single Centre Experience

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia

Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy

Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

Allogeneic Stem Cell Transplant in First Complete Remission Overcomes the Poor Prognosis Associated with the FLT-3 Internal Tandem Duplication in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only